NCT06361836

Study of Single Doses of SBT777101 in Subjects With Hidradenitis Suppurativa

A Phase 1 Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Activity of Single Ascending Doses of SBT777101 in Subjects With Hidradenitis Suppurativa

• Status: Active Not Recruiting
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 24 (estimated)
• Sponsor: Sonoma Biotherapeutics, Inc. · Industry
• Sex: All
• Age: 18 Years – 70 Years
• Healthy volunteers: Not accepted

Summary

This study will test the safety and effects of SBT777101 when given as a single dose to subjects with hidradenitis suppurativa. Increasing dose levels will be given after the safety at lower dose levels is shown.

Detailed description

The study evaluates the safety and effects of a novel regulatory CARTreg cell-based autoimmune and inflammatory disease therapy for the treatment of hidradenitis suppurativa. The therapy is an autologous (using the patient's own cells) Treg cell therapy that targets proteins in the inflamed, disease-associated tissue, with the aim to dampen inflammation and restore balance to the immune system.

Conditions

• Hidradenitis Suppurativa

Interventions

Type	Name	Description
BIOLOGICAL	SBT777101	Experimental treatment

Timeline

• Start date: 2024-10-09
• Primary completion: 2026-11-01
• Completion: 2026-11-01
• First posted: 2024-04-12
• Last updated: 2026-02-20

Locations

6 sites across 1 country: United States

Regulatory

• FDA-regulated drug study